-
Mental Health Provider Expands Psychedelic-Assisted Therapy For Chronic & Serious Medical Illnesses
Friday, October 28, 2022 - 2:28pm | 449Numinus Wellness Inc. (OTCQX: NUMIF) announced the launch of its new clinical program, ketamine for chronic and serious medical illness, to be first introduced at Utah, BC and Quebec clinics and then expanded to Numinus' remaining facilities. The company’s model includes...
-
Mushroom Tea For Use In Psychedelic Research Developed By Numinus Wellness
Wednesday, October 5, 2022 - 9:48pm | 436Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based psychedelic-assisted therapies, announced that its research division, Numinus Bioscience, has developed a psilocybin-containing tea bag for use in clinical research and...
-
Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder
Wednesday, March 9, 2022 - 5:08pm | 492Novamind Inc. (OTCQB: NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site. "The Psilocybin Trial is a...
-
Psychedelic Medicine For End-Of-Life And Palliative Care Patients: Novamind Launches Treatment Program
Thursday, October 7, 2021 - 4:48pm | 588Novamind (Canadian: NM) (OTCQB: NVMDF), a company in the psychedelics space that operates several mental health clinics in Utah, announced a new program for palliative care patients experiencing chronic and serious illnesses. The program will take place at Novamind’s recently-opened...